The Study of Abatacept in Combination With Etanercept

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00162279

Enrollment

141

Registered

2005-09-13

Start date

2000-10-31

Completion date

2007-02-28

Last updated

2010-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

Interventions

DRUGAbatacept

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All subjects who had completed the short term portion of IM101-101.

Design outcomes

Primary

Measure	Time frame
Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone	at 6 months

Secondary

Measure	Time frame
ACR 50 and 70 will be evaluated	at 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026